Search results
Results from the WOW.Com Content Network
2C-B (4-bromo-2,5-dimethoxyphenethylamine), also known as Nexus, is a synthetic psychedelic drug of the 2C family, mainly used as a recreational drug. [2] [1] [4] It was first synthesized by Alexander Shulgin in 1974 for use in psychotherapy.
The Brand and Generic Name Index is located at the front of CPS. It is the most comprehensive list of current brand and generic drugs in Canada, and also includes discontinued products. This section is also referred to as the green section because of the green border on the right side of the pages.
Pages in category "Pharmaceutical companies of Canada" The following 24 pages are in this category, out of 24 total. This list may not reflect recent changes .
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Canada is the world's eighth-largest economy as of 2022, with a nominal GDP of approximately US$2.2 trillion. [1] It is a member of the Organisation for Economic Co-operation and Development (OECD) and the Group of Seven (G7), and is one of the world's top ten trading nations , with a highly globalized economy.
2C-B-aminorex (2C-B-AR) is a recreational designer drug with psychedelic effects. It is a substituted aminorex derivative which was first identified in Sweden in June 2019. [ 1 ] Structurally, it is a hybrid of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and aminorex.
Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion. [5] By 2023, Apotex employed close to 8,000 people as Canada's largest drug manufacturer, with over 300 products selling in over 115 countries.
βk-2C-B is a designer drug, more specifically it is the beta keto analogue of the controlled substance 2C-B (2,5-dimethoxy-4-bromophenethylamine) which was first synthesized by Alexander Shulgin. It is unknown who first synthesized βk-2C-B, but it first appeared on the market mid-2013 as a recreational drug. [1]